Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
-

-

-
-
-
-
 
WKN: A116DD / Name: CymaBay / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Cymabay Therapeutics Inc Stock

Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Cymabay Therapeutics Inc stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Cymabay Therapeutics Inc in the next few years

Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Cons
?
S********** s********
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Cymabay Therapeutics Inc vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Cymabay Therapeutics Inc - - - - - - -
Evolus Inc 0.690% 8.209% 15.079% 72.619% 60.221% 116.418% -
Ardelyx Inc. 0.300% -4.516% -0.739% 42.819% -7.093% 375.221% 21.783%
Coherus Bioscien. -6.590% -12.403% -10.907% -75.986% -66.546% -93.220% -94.772%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-11-11

Assessing the financial standing of CymaBay, a frontrunner in the Biotechnology & Medical Research industry, the company portrays a mixed bag of circumstances. In one vein, its financial posture wrestles with certain impediments, while, on the other hand, it arms itself with potential growth drivers.

Analysis of financial ratios and its balance sheet unfolds a few favorable facets.

On the flip side, a host of challenges warrants immediate attention.

Comments

Sell Cymabay Therapeutics Inc
Show more

Buy Cymabay Therapeutics Inc
Show more

Prediction Buy
Perf. (%) 76.76%
Target price 11.726
Change
Ends at 08.02.18

(Zielkurs erreicht)
Show more